Drug used in renal osteodystrophy:
**Core Concept**
Renal osteodystrophy is a bone disease caused by chronic kidney disease (CKD), characterized by abnormal bone mineralization and structure. The pathophysiology involves disturbances in calcium and phosphate homeostasis, leading to secondary hyperparathyroidism and osteomalacia or osteitis fibrosa cystica.
**Why the Correct Answer is Right**
The treatment of renal osteodystrophy involves managing hyperphosphatemia, hyperparathyroidism, and bone mineralization defects. **Calcitriol**, the active form of vitamin D, is used to suppress parathyroid hormone (PTH) secretion, reduce phosphate absorption from the gut, and improve bone mineralization. **Calcitriol** acts by binding to vitamin D receptors (VDRs) in the parathyroid gland and kidney, leading to decreased PTH secretion and increased calcium absorption from the gut.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because while phosphate binders are used to control hyperphosphatemia, they do not directly address the bone mineralization defects or hyperparathyroidism associated with renal osteodystrophy.
* **Option B:** This option is incorrect because bisphosphonates are used to treat osteoporosis and Paget's disease, but not the specific bone abnormalities seen in renal osteodystrophy.
* **Option C:** This option is incorrect because erythropoietin analogs are used to treat anemia of CKD, but not the bone mineralization defects or hyperparathyroidism associated with renal osteodystrophy.
**Clinical Pearl / High-Yield Fact**
Remember that **calcitriol** is the active form of vitamin D used to treat renal osteodystrophy, but it should be used with caution in patients with CKD, as it can worsen hypercalcemia.
**Correct Answer: C. Calcitriol**